Evidence map›Paper›PMID 33106290›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.

Joyce K Hwang, Neeraj Agarwal, James Brugarolas, Tian Zhang

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Joyce K HwangDepartment of Medicine, Duke University, Durham, North Carolina.
Neeraj AgarwalHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-1076-0428
James BrugarolasKidney Cancer Program, Department of Medicine, University of Texas-Southwestern, Dallas, Texas.
Tian ZhangDepartment of Medicine, Duke University, Durham, North Carolina. tian.zhang2@duke.edu.
Duke University · USHuntsman Cancer Institute · USThe University of Texas Southwestern Medical Center · US

Funding

University of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI James Brugarolas · 2016 to 2026
$24.7M
NCI NIH HHS P50 CA196516
6 · The paper itself

Abstract

Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHippo Signaling PathwayHumansImmunotherapyIpilimumabNivolumabProtein Serine-Threonine KinasesSunitinibIpilimumabNivolumabProtein Serine-Threonine KinasesSunitinib

Identifiers

PMID33106290
PMCPMC7785667
OpenAlexW3093590628

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.